The principle of action of sparsentane and its application in the treatment of kidney disease

Sparsentan, as an innovative oral dual endothelin-angiotensin receptor antagonist (DEARA), has recently attracted much attention in the field of renal disease treatment. Its unique principle of action and significant clinical application results have brought new treatment opportunities to patients with kidney disease. This article will take an in-depth look at how sparsentane works and its practical applications in the treatment of kidney disease.

The main principle of action of sparsentan is that it can simultaneously antagonize endothelin type A receptor (ETA) and angiotensin II type 1 receptor (AT1R). Endothelin and angiotensin II are two bioactive substances that play a central role in the pathogenesis of various kidney diseases. Sparsentane can selectively bind to these two receptors, thereby blocking their activity, thereby achieving the effect of treating kidney diseases.

In the treatment of kidney disease, the clinical application of sparsentane has been widely recognized. Taking the treatment of IgA nephropathy as an example, sparsentane has shown obvious therapeutic effects. In the phase 3 clinical trial called PROTECT, patients treated with sparsentan showed a significant reduction in proteinuria levels after 36 weeks compared with irbesartan (a decrease of 49.8%, compared with 15.1% in the irbesartan group), demonstrating its superior efficacy.

United StatesThe FDA has approved sparsentan for the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for rapid progression, specifically those with a urine protein to creatinine ratio (UPCR) greater than or equal to 1.5 g/g. However, it should be noted that sparsentan also has certain side effects and contraindications. Therefore, doctors need to conduct personalized treatment according to the patient's specific conditions when using it, and closely monitor changes in the patient's condition.

In summary, sparsentan, as a new dual endothelin-angiotensin receptor antagonist, shows significant advantages and great potential in the field of renal disease treatment. Its unique principle of action and significant clinical effects provide new treatment paths for patients with kidney disease. Although the drug is currently only sold in overseas markets and has a higher price, which increases the financial burden on patients, the Lucius version of the generic drug on the Lao market provides a more economical option. This generic drug is sold in the format of 400mg*30 tablets, with a price of about more than 7,000 yuan per box, providing a feasible treatment option for patients with limited financial conditions.